Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell’s existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65415-weill-cornell-medical-college-belfer-cancer-research-building-opening
Global health service company Cigna Corporation (NYSE: CI) today unveiled a new initiative championing its whole person approach to health and well-being. The company is bringing together three cultural icons, Queen Latifah, Nick Jonas and Ted Danson, to encourage everyone to schedule their annual check-up and talk openly and honestly with their health care providers about how they are feeling, physically and emotionally.
Filmed in Los Angeles, the campaign takes a public service message approach and features the three influencers taking unique steps to find balance in their hectic personal and professional lives. Using light humor, they each address the impact that widespread and relatable feelings, such as stress and loneliness, can have on overall health and well-being.
To view the multimedia release go to:
https://www.multivu.com/players/English/8454551-cigna-latifah-jonas-danson-go-know-take-control/
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and expert services at this year's American Society of Health-System Pharmacists (ASHP) 2017 Midyear Meeting being held in Orlando from Dec. 3-7.
With direct medical costs associated with medication errors reaching $21 billion worldwide, innovative strategies must be developed to address the grand health challenges associated with medication management. BD has been evolving its focus to re-invent medication management with integration of the company’s technologies, analytics and expert services that aim to close the communication gaps across disparate solutions. The BD HealthSight platform connects systems and processes to help hospitals and health systems drive a safer, more efficient medication management process.
To view the multimedia release go to:
https://www.multivu.com/players/English/8198551-bd-healthsight-platform-ashp-2017/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology.
The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks.
To view the multimedia release go to:
https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
High school freshman Nina McDonald recalls simply running for the ball during middle school soccer practice when she felt a pop in her knee, followed by excruciating pain. As she fell to the ground, she remembers thinking she would never be able to play her favorite sport again.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cayennemedical/46933/
The foetus moves its mouth in an exaggerated manner when it hears a human voice. This occurs from the 16th week of pregnancy (with a foetus of 11cm) and only when the voice reaches it through an intravaginal device developed for this purpose. This is one of the conclusions of the study presented by Dr. Álex García-Faura, the Scientific Director of the Institut Marquès, at the 25th European Congress of Perinatal Medicine held in Maastricht (Netherlands).
The study finds that babies hear practically no external noise and only react when sound reaches them through the vagina, which confirms that they hardly hear voices through the mother’s abdomen. Their reactions were studied using Babypod®, a small device that is inserted into the vagina like a tampon and is connected to a mobile phone, enabling the voice of the mother or anyone else to reach the foetus.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7859951-institut-marques-babies-react-mother-voice/
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Oro Valley Audiology
2542 E Vistoso Commerce Loop Rd, Tucson, AZ 85755, USA
(520) 825-4770
http://hearintucson.com
https://www.google.com/maps?cid=7471816986561274177
https://www.google.com/search?q=Oro+Valley+Audiology&kponly&kgmid=/g/1thx4hd3
As the name suggests, and audiologist is a health-care professional who concentrates on the medical diagnoses, recognition, tracking and treatment of conditions of the auditory and vestibular parts of the ear. These specialists dispense hearing aids, manage and fix up hearing problems and evaluate candidacy for cochlear implants. An audiologist helps style and carry out individual and industrial hearing safety programs, newborn hearing screening programs, and school hearing screening programs.
Audiologists have training in anatomy and physiology, hearing aids, cochlear implants, electrophysiology, acoustics, psychophysics, neurology, vestibular function and evaluation, balance disorders, therapy and indication language. Unfortunately, hearing loss is prevalent throughout the U.S.
